Vaccines & Immunization VIPS WHO GAVI UNICEF BMGF PATH
In 2017, WHO, PATH, the Bill and Melinda Gates Foundation, UNICEF and Gavi launched the Vaccine Innovation Prioritisation Strategy (VIPS), with the aim to drive vaccine product innovation to better meet country needs and support Alliance goals on immunisation coverage and equity.
Product innovation refers to completely new vaccine products or adaptations to existing products that provide measurable financial or programmatic benefits to low and middle income countries (LMICs) — such as increased coverage and equity (e.g. by overcoming a "last mile" barrier) or improved vaccine effectiveness.
Through VIPS, the Alliance strives to:
- Understand countries' needs to consider the financial and non-financial impact of innovations
- Develop common principles to measure the benefits of product innovations
- Convene a platform to articulate a clear and aligned perspective on priority product innovations in development
- Communicate these priorities to provide greater clarity for manufacturers or partners to inform investment decisions
The original VIPS survey closed on 30 September 2018. Contact for follow-up at the time: Anna Osborne (aosborne@gavi.org).
Auteur(s) : Pretty Mubaiwa (relai de l'enquête VIPS)
Publication d'origine : 10 septembre 2018
📎 Document Word : VIPS Survey — invitation email to country networks (WHO / PATH / Gates / UNICEF / Gavi)
Source : Africa Resource Centre
Articles connexes